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Abstract
Background: Insulin-like growth factor binding protein 2 (IGFBP2) is overexpressed in ovarian
malignant tissues and in the serum and cystic fluid of ovarian cancer patients, suggesting an
important role of IGFBP2 in the biology of ovarian cancer. The purpose of this study was to assess
the role of increased IGFBP2 in ovarian cancer cells.
Results: Using western blotting and tissue microarray analyses, we showed that IGFBP2 was
frequently overexpressed in ovarian carcinomas compared with normal ovarian tissues.
Furthermore, IGFBP2 was significantly overexpressed in invasive serous ovarian carcinomas
compared with borderline serous ovarian tumors. To test whether increased IGFBP2 contributes
to the highly invasive nature of ovarian cancer cells, we generated IGFBP2-overexpressing cells
from an SKOV3 ovarian cancer cell line, which has a very low level of endogenous IGFBP2. A
Matrigel invasion assay showed that these IGFBP2-overexpressing cells were more invasive than
the control cells. We then designed small interference RNA (siRNA) molecules that attenuated
IGFBP2 expression in PA-1 ovarian cancer cells, which have a high level of endogenous IGFBP2.
The Matrigel invasion assay showed that the attenuation of IGFBP2 expression indeed decreased
the invasiveness of PA-1 cells.
Conclusions: We therefore showed that IGFBP2 enhances the invasion capacity of ovarian cancer
cells. Blockage of IGFBP2 may thus constitute a viable strategy for targeted cancer therapy.
Background
Ovarian cancer is the most lethal gynecological malig-
nancy. Indeed, epithelial ovarian cancer is detected at a
late clinical stage in as much as 75% of patients, in whom
the overall survival rate is a dismal 14–30% [1]. Hindering
the development of effective treatments for the cancer is
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logical behavior of ovarian cancer are poorly understood.
Implicated in both ovarian tumorigenesis and physiolog-
ical follicular proliferation are the insulin-like growth fac-
tor I (IGF-I) and IGF-II systems. IGFs are regulated by at
least six members of the IGF binding protein (IGFBP)
family. High levels of IGFBP2 were detected in the serum
or cystic fluid from patients with ovarian cancer compared
with those with benign and borderline tumors [2-4]. A
recent study further showed that IGFBP2 mRNA was over-
expressed to a greater extent in advanced-stage serous
ovarian cancer than normal ovarian tissue [5]. In addi-
tion, the increase in IGFBP2 expression was found to cor-
relate positively with the levels of the serum tumor marker
CA125 [4]. The progression-free interval and overall sur-
vival have also proved to be significantly shorter in
patients with a high serum level of IGFBP2 at diagnosis
than in those with lower levels [6]. Taken together, these
data suggest an important role for IGFBP2 in the biology
of ovarian cancer.
IGFBP2 is also overexpressed in a wide spectrum of other
cancers, including glioma, prostate cancer, synovial sar-
coma, neuroblastoma, colon cancer, adrenocortical can-
cer, lung cancer, Wilms' tumor, and hepatoblastoma [7-
17]. The overexpression of IGFBP2 also correlates with the
aggressiveness of some tumors, including prostate cancer,
hepatoblastoma and glioma [10,17,18], suggesting that
IGFBP2 possesses a carcinogenic property. The observa-
tion that IGFBP2 has an RGD motif suggests that IGFBP2
modulates the integrin/cytoskeleton system. Indeed,
IGFBP2 was recently found to interact with the alpha v
beta 3 and alpha 5 beta 1 integrins [19,20]. In addition,
IGFBP2 has been found to stimulate the growth of pros-
tate cancer cells, an effect that can be blocked by MAP-
kinase and PI3-kinase inhibitors [21]. IGFBP2 was also
found to be co-expressed with the vascular endothelial
growth factor in pseudopalisading glioma cells surround-
ing tumor necrosis [22]. Further, IGFBP2 enhances glioma
cell invasion by increasing invasion-related genes includ-
ing MMP2 [23]. These findings collectively suggest that
IGFBP2 plays a key role in human cancer development.
In this study, we found that overexpression of IGFBP2
enhanced the invasiveness of ovarian cancer cells. Further,
attenuation of IGFBP2 expression by siRNA reduced the
invasiveness of ovarian cancer cells.
Results and Discussion
IGFBP2 is associated with invasive epithelial ovarian 
carcinoma
We first performed western blotting analysis using frozen
tissue specimens, which consisted of four paired normal
and carcinomatous ovarian tissues, one normal ovarian
tissue, and three unpaired ovarian carcinoma tissues. This
result showed that IGFBP2 was frequently overexpressed
in ovarian cancer tissues compared with normal ovarian
tissues (Figure 1A). We then compared the expression of
IGFBP2 in normal ovaries, borderline serous ovarian
tumors, and invasive serous ovarian carcinomas using a
tissue microarray, which showed that IGFBP2 was
expressed at significantly different levels between normal
tissues and borderline tumors (p = 0.03) and between bor-
derline tumors and invasive carcinomas (p = 0.03) (Figure
1B, Table 1). Because borderline ovarian tumors have no
obvious stromal invasion or infiltrative growth in contrast
with invasive ovarian carcinoma [24], this finding sug-
gests that IGFBP2 overexpression could induce invasion
nature of ovarian cancer.
IGFBP2 enhances the invasiveness of ovarian cancer cells
Thus far, the biological or pathophysiological role of
IGFBP2 in ovarian cancer is unknown. To elucidate the
role of increased IGFBP2 in ovarian cancer, we therefore
generate IGFBP2-overexpressing cells. To obtain suitable
cells for this study, we first examined the endogenous
expression of IGFBP2 in six ovarian cancer cell lines:
NIH:OVCAR3, SKOV3, PA-1, OV-90, TOV-112D, and
TOV-21G. IGFBP2 was expressed at different levels in all
six cell lines (Figure 2A). Both SKOV3 and OV-90 cells
showed very low levels of endogenous IGFBP2;
NIH:OVCAR3, PA-1, and TOV-112D cells expressed
IGFBP2 at high levels; and TOV-21G cells expressed
IGFBP2 at a relatively moderate level. We thus selected
SKOV3 cell line and generated two vector transfected
clones and three IGFBP2-overexpressing clones by trans-
fection (Figure 2B).
We studied the cellular phenotype of IGFBP2-overexpress-
ing cell lines. Similar to observations in gliomas [23], we
did not observe differences in cell proliferation (data not
shown). This is contrary to the findings in prostate cancer,
adenocortical cancer and neuroblastoma, in which
IGFBP2 has been found to stimulate cell proliferation
[21,25,26]. We then assessed the invasive capacity by a
Matrigel in vitro invasion assay. The invasiveness of the
IGFBP2-overexpressing cells was 1.8- to 2.9-fold greater
than that of the vector-alone-transfected cells (p < 0.05;
Figure 2C). Our tissue microarray findings were consistent
with this finding. This suggests that acquisition of IGFBP2
is a very important step in the penetration of the extracel-
lular matrix by ovarian cancer cells, which they may need
to do before they can move to adjacent tissue and the lym-
phovascular space. This provides a site for occult progres-
sion or the formation of recurrent ovarian cancers.
Indeed, ovarian cancer frequently spreads through the
lymphatic system [27]. In fact, in one study, 20% of
patients with early-stage invasive ovarian carcinoma
whose tumors appeared to be confined to the ovary (stage
I disease) were found to have lymph node metastasis [28].Page 2 of 8
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Molecular Cancer 2005, 4:7 http://www.molecular-cancer.com/content/4/1/7Overexpression of IGFBP2 in ovarian carcinomaFigure 1
Overexpression of IGFBP2 in ovarian carcinoma. (A) Western blotting analysis in paired normal and cancer tissues (N1 to T4), 
one normal ovarian (N5) and 3 unpaired ovarian cancer tissues (T6 to T8) showed frequent overexpression of IGFP2 in ovar-
ian cancer tissues compared with normal ovarian tissues. (N: normal ovarian tissue, T: ovarian cancer tissue). (B) Expression of 
IGFBP2 in normal ovary (100×), borderline ovarian tumor (100×), and invasive ovarian carcinoma (200×) using tissue microar-
ray. IGFBP2 was expressed at greater level in invasive ovarian carcinoma than normal and borderline ovarian tumors.
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patients without lymph node metastasis [29]. Our study
therefore also provides strong evidence that IGFBP2 could
be a factor indicating a poor prognosis.
Disruption of IGFBP2 inhibits ovarian cancer cell invasion
The observation that IGFBP2 increased the invasive capac-
ity of ovarian cancer cells and those of previous studies
prompted us to determine whether IGFBP2 could serve as
a target of therapy for ovarian cancer. We used PA-1 ovar-
ian cancer cells for this experiment because they express a
high level of endogenous IGFBP2 and show a relatively
high invasive capacity compared with other ovarian can-
cer cell lines. We designed siRNAs for four different target
sites of IGFBP2 mRNA because not all siRNAs were
expected to effectively attenuate IGFBP2 expression. West-
ern blotting analysis showed that the IGFBP2 level after
siRNA-3 transfection was comparable to the levels after
the transfection of Lamin A/C and negative control siRNA
in OVCAR3 and PA-1 ovarian cancer cell lines, suggesting
that the siRNA-3 was not effective (Figure 3A). Consider-
ing that not all siRNA molecules work, this was not sur-
prising. Therefore, we used siRNA-3-transfected cells as a
negative control. siRNA-1 and siRNA-4 attenuated
IGFBP2 expression in the PA-1 cells more than did either
siRNA-2 or siRNA-3 (Figure 3B). Likewise, in the invasion
assay, the invasive capacity of the cells transfected with
siRNA-1 or siRNA-4 was significantly decreased compared
with that of the cells transfected with siRNA-2 or siRNA-3
(p < 0.05; Figure 3C). These findings therefore support to
the notion that IGFBP2 is a viable target of therapy for
ovarian cancer.
Conclusions
In this study, we showed that IGFBP2 was significantly
overexpressed in invasive ovarian carcinomas compared
with borderline ovarian tumors as well as normal ovarian
tissues and that IGFBP2 increases invasion capability of
ovarian cancer cells. These results provide evidence that
IGFBP2 could promote ovarian cancer progression by
augmenting the invasion potential. Although further
investigations of molecular mechanisms are required, our
findings using siRNA study support IGFBP2 as a novel tar-
get for the treatment of ovarian cancer.
Methods
Ovarian tissues and cell lines
Ovarian cancer and normal control tissues were obtained
from The University of Texas M. D. Anderson Cancer
Center tumor tissue bank with the approval of the Institu-
tional Review Board. The ovarian cancer cell lines
NIH:OVCAR3, SKOV3, OV-90, TOV-112D, TOV-21G,
and PA-1 were purchased from the American Type Culture
Collection (Manassas, VA). NIH:OVCAR3 cells were
maintained in RPMI 1640 medium supplemented with
20% fetal bovine serum (FBS); SKOV3 and PA-1 cell were
maintained in McCoy's 5a medium and Dulbecco's mod-
ified Eagle medium (DMEM)/F12, respectively, supple-
mented with 10% FBS; OV-90, TOV-112D, and TOV-21G
cells were maintained in a 1:1 mixture of MCDB 105
medium and medium 199, supplemented with 15% FBS.
All cells were kept at 37°C in a humidified atmosphere
with 5% CO2. Media were routinely changed every 3 days.
Construction of progression tissue microarray for ovarian 
serous tumors
Formalin-fixed, paraffin-embedded archival tissue blocks
from ovarian cancer patients who had undergone surgery
at The University of Texas M. D. Anderson Cancer Center
between 1990 and 2001 were used to construct progres-
sion tissue microarrays according to previously described
methods [30]. The progression tissue microarray
Table 1: Increasing expression of IGFBP2 with progression of ovarian serous tumors*.
Tissue IGFBP2 expression (Scores) P value
3 2 1 0
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*Each diamond represents one case (Mann-Whitney U test).
#P value between normal ovaries and borderline ovarian tumors
§P value between borderline ovarian tumors and invasive ovarian carcinomasPage 4 of 8
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Molecular Cancer 2005, 4:7 http://www.molecular-cancer.com/content/4/1/7IGFBP2 overexpressing promotes ovarian cancer cell invasionFigure 2
IGFBP2 overexpressing promotes ovarian cancer cell invasion. (A) IGFBP2 expression of six ovarian cancer cell lines. The 
western blotting analysis shows that the expression level of IGFBP2 is heterogeneous in cell lines. SKOV3 and OV-90 ovarian 
cancer cell lines have very low endogenous IGFBP2. NIH:OVCAR3, PA-1 and TOV-112D have high levels of IGFBP2 expres-
sion whereas TOV-21G has relatively moderate expression of IGFBP2. (B) Two vector transfected clones and three IGFBP2 
stable clones with different expression level were obtained. The expression of IGFBP2 was determined by western blotting 
analysis (p: parental SKOV3 cell line, v: vector transfected cell lines, b: IGFBP2 stable cell lines). (C) The invasion capacity of 
stable clones showed that IGFBP2 overexpressing cells have invasion potential as 1.84 – 2.89 fold as parental and vector trans-
fected cells. (*p < 0.05)
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Molecular Cancer 2005, 4:7 http://www.molecular-cancer.com/content/4/1/7Attenuation of IGFBP2 inhibits ovarian cancer cell invasionFigure 3
Attenuation of IGFBP2 inhibits ovarian cancer cell invasion. (A) Western blotting analysis of IGFBP2 after transfection of 
siRNA in OVCAR3 and PA-1. 4 siRNAs inhibit the IGFBP2 with various levels. IGFBP2 levels of siRNA-3 transfected cells have 
similar to those of Lamin A/C and negative control transfected cells. (B) Four different siRNAs were transfected to PA-1 ovar-
ian cancer cells which has high endogenous IGFBP2. Different inhibiting levels of IGFBP2 were determined by western blotting 
analysis. siRNA-1 and -4 were working better than siRNA-2 and -3. (C) The invasion activity after 72 hours of siRNA transfec-
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Molecular Cancer 2005, 4:7 http://www.molecular-cancer.com/content/4/1/7consisted of normal ovarian surface epithelium from 6
individuals, serous borderline tumors from 17 patients,
and invasive serous carcinomas from 40 patients. Tissue
cores with a diameter of 1.0 mm were obtained from each
sample and assembled into two separate tissue array
blocks.
Immunohistochemistry studies
Polyclonal antibody against IGFBP2 (c-18; Santa Cruz
Biotechnology, Inc., Santa Cruz, CA) was used in the
immunohistochemistry studies. This antibody is specific
and does not cross-react with other isoforms of IGFBP. A
standard indirect immunoperoxidase procedure (ABC-
Elite; Vector Laboratories, Burlingame, CA) was used for
all stains. In brief, antigen retrieval was performed by first
placing unstained slides in a steamer for 25 min. The anti-
body against IGFBP2 (in a 1:1000 dilution) was overlaid
on the tissue sections of tissue arrays, and incubation was
performed at 4°C overnight. Secondary antibody incuba-
tion was performed at room temperature for 60 min.
Mayer's hematoxylin nuclear stain was used as a counter-
stain. Staining intensity was graded on a 0–3 scale, where
0 = no staining as assessed by staining with anti-goat sec-
ondary antibody alone, 1 = weak (<10%), 2 = moderate
(10–50%), and 3 = strong (50–100%). The results of the
immunohistochemistry studies were statistically analyzed
using a Mann-Whitney nonparametric U test.
Stable clone establishment
To establish stable cell lines that overexpressed IGFBP2,
we transfected SKOV3 ovarian cancer cell lines with a
pcDNA3.1 expression vector encoding IGFBP2 cDNA
using FuGENE6 reagent (Roche Diagnostics Corporation,
Indianapolis, IN). Transfected cells were subsequently
selected in the presence of G418 (300 µg/ml) for 5 weeks.
The expression of IGFBP2 clones was determined from
western blots of cell extracts with anti-IGFBP2 antibody
(C-18). Two vector-transfected cell lines and three IGFBP2
stable cell lines were used in this study. Established stable
cells were maintained without antibiotics.
Western blot analysis
Equal amounts of proteins from the total cell lysates was
separated by 10% SDS-PAGE and transferred electropho-
retically to a Hybond ECL nitrocellulose membrane
(Amersham Pharmacia Biotech, Chicago, IL). The mem-
brane was blocked in 5% skim milk in 1× PBS and probed
with a 1:1000 dilution of a goat polyclonal anti human
IGFBP2 (C-18) overnight at 4°C. An enhanced chemilu-
minescence kit (ECL; Amersham Pharmacia Biotech, Pis-
cataway, NJ) was used to visualize the proteins.
In vitro chemoinvasion assay
We used 24-well BioCoat Matrigel invasion chambers
(Becton Dickinson Labware, Bedford, MA) with an 8-µm
pore polycarbonate filter coated with Matrigel to measure
chemoinvasion. The lower compartment contained 0.75
ml of medium with 0.5% FBS as a chemoattractant. In the
upper compartment, 5 × 104 to 2 × 105 cells/well were
placed in triplicate wells and incubated for 22 h at 37°C
in a humidified incubator with 5% CO2. After incubation,
the cells that had passed through the filter into the lower
wells were stained with Giemsa (Fisher Scientific, Orange-
burg, NY) and counted by analyzing images under a
microscope using software program as described previ-
ously [31]. All assays were repeated at least three times.
Student's t-test was used to analyze the differences in the
invasion rates between control cell lines and stable cell
lines. A p value of <0.05 was considered statistically
significant.
siRNA transfection
Four different siRNA molecules designed for IGFBP2
mRNA and siRNA molecules for Lamin A/C and negative
control were synthesized and purified (Qiagen, Valencia,
CA). siRNA that targets Lamin A/C and siRNA that bears
no homology with relevant human genes was used as a
negative control.
AATGGCGATGACCACTCAGAA was the target sequence
for siRNA1; AAGGGTGGCAAGCATCACCTT was the tar-
get sequence for siRNA2; AAGCGCCGGGACGCCGAG-
TAT was the target sequence for siRNA3;
AACCTCAAACAGTGCAAGATG was the target sequence
for siRNA4; AACTGGACTTCCAGAAGAACA was the tar-
get sequence for Lamin A/C; and AATTCTCCGAACGTGT-
CACGT was the target sequence for the negative control.
siRNAs were dissolved in siRNA suspension buffer to a
final concentration of 20 µM, and the mixture was heated
to 90°C for 1 min and incubated at 37°C for 60 min. PA-
1 ovarian cancer cells (2 × 105) were plated to a 6-well
plate and allowed to adhere for 24 h; the confluency of the
cell monolayer at the time of transfection was 40–60%. 5
µg of siRNA and 15 µl of RNAiFect Transfection Reagent
(Qiagen, Valencia, CA) was used. The cells were incubated
under normal cell culture conditions. All assays were per-
formed 72 h after treatment.
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